Ozempic for Type 2 Diabetes: A1C, Heart, Kidneys and Insulin

Ozempic (semaglutide) is an FDA-approved once-weekly injection for adults with type 2 diabetes. It is used alongside diet and exercise to lower blood sugar, either on its own or with other diabetes medicines such as metformin, an SGLT2 inhibitor or insulin. In the trials on its label, Ozempic lowered A1C by about 1.2 to 2.1 percentage points, depending on the dose and the comparison, and people lost weight too. The label also carries two outcome indications for adults with type 2 diabetes: lowering the risk of heart attack, stroke and cardiovascular death in those with established cardiovascular disease, and, since January 2025, lowering the risk of kidney decline, kidney failure and cardiovascular death in those with chronic kidney disease. Ozempic is not insulin and is not approved for type 1 diabetes.

Below: how it works, where it usually fits in U.S. diabetes care, what the trials show for blood sugar, heart and kidneys, how it combines with metformin, SGLT2 inhibitors, sulfonylureas and insulin, what to monitor, and what to do if it is not working.

What Ozempic is approved for

According to the current FDA label, Ozempic is indicated:

• as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes;
• to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack or nonfatal stroke) in adults with type 2 diabetes and established cardiovascular disease;
• to reduce the risk of sustained decline in kidney function (eGFR), end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

Its safety and effectiveness have not been established in children. A tablet form sold as Ozempic tablets (1.5, 4 and 9 mg once daily) has been available since May 4, 2026, for adults with type 2 diabetes; see the Ozempic pill. Weight management is not an Ozempic indication; that is Wegovy's label (see Ozempic for weight loss).

How Ozempic works in type 2 diabetes

Semaglutide is a GLP-1 receptor agonist: it imitates a hormone the gut releases after meals. It prompts the pancreas to release insulin only when blood sugar is elevated, reduces the release of glucagon (a hormone that raises blood sugar), slows stomach emptying and lowers appetite. Because the insulin response depends on glucose, Ozempic alone rarely causes low blood sugar. In the 30-week monotherapy trial, no one on Ozempic had severe hypoglycemia. The risk rises when it is combined with insulin or a sulfonylurea.

Semaglutide has a half-life of about one week, so one injection covers a week, and steady levels are reached after four to five weeks of dosing. Treatment begins at 0.25 mg for four weeks (a starter dose, not meant to control blood sugar), then 0.5 mg. If more control is needed, the dose can go to 1 mg and then to 2 mg, each after at least four weeks. For kidney protection in people with chronic kidney disease, the label specifies 1 mg. Details: Ozempic dosage.

Where Ozempic fits in diabetes treatment

U.S. diabetes care is guided largely by the American Diabetes Association's annual Standards of Care and by what insurance plans will pay for. In broad terms:

Situation	Where a GLP-1 such as Ozempic usually comes in
Newly diagnosed, no heart or kidney disease	Lifestyle changes plus metformin is a common start; a GLP-1 may be added if A1C stays above goal, or used first when metformin is not tolerated
Established cardiovascular disease	A GLP-1 with proven heart benefit, such as Ozempic, or an SGLT2 inhibitor is recommended regardless of A1C
Chronic kidney disease	SGLT2 inhibitors and Ozempic both have kidney outcome evidence; many people take both
Heart failure	An SGLT2 inhibitor is usually the first choice; a GLP-1 may be added
Obesity alongside diabetes	GLP-1 drugs (or tirzepatide) are favored because they lower both glucose and weight
An injectable is needed	A GLP-1 is generally tried before insulin unless A1C is very high or there are signs of insulin deficiency (heavy thirst, frequent urination, weight loss)
Still above goal on a GLP-1	Basal insulin is added; metformin usually continues

Insurers often add their own conditions, such as prior authorization or a metformin trial first; see how to get Ozempic. Medicare Part D plans generally cover Ozempic for type 2 diabetes.

Blood sugar results: what the trials show

These are the main glycemic trials summarized on the FDA label. A1C is shown as the change in percentage points from baseline.

Trial	Length	Comparison	A1C change	Reached A1C under 7%	Weight change
Monotherapy (SUSTAIN 1)	30 weeks	Ozempic 0.5 mg / 1 mg / placebo	-1.4 / -1.6 / -0.1	73% / 70% / 28%	-3.8 / -4.7 / -1.2 kg
Add-on to metformin and/or a TZD	56 weeks	Ozempic 0.5 mg / 1 mg / sitagliptin	-1.3 / -1.5 / -0.7	66% / 73% / 40%	-4.2 / -5.5 / -1.7 kg
Add-on to metformin with or without a sulfonylurea	56 weeks	Ozempic 1 mg / exenatide ER 2 mg	-1.4 / -0.9	62% / 40%	-4.8 / -2.0 kg
Add-on to metformin with or without a sulfonylurea	30 weeks	Ozempic 0.5 mg / 1 mg / insulin glargine	-1.2 / -1.5 / -0.9	55% / 66% / 40%	-3.2 / -4.7 / +0.9 kg
Add-on to basal insulin	30 weeks	Ozempic 0.5 mg / 1 mg / placebo	-1.3 / -1.7 / -0.2	56% / 73% / 13%	-3.5 / -6.0 / -1.2 kg
SUSTAIN FORTE	40 weeks	Ozempic 1 mg / 2 mg	-1.9 / -2.1	56% / 64%	-5.6 / -6.4 kg

Source: Ozempic prescribing information, section 14. Baseline A1C in these trials was roughly 8.0% to 8.9%; people starting higher tend to see larger drops. In the SUSTAIN FORTE trial, the 2 mg dose beat 1 mg on A1C by 0.2 points, while the weight difference between the two doses was not statistically significant.

Heart protection: SUSTAIN-6

SUSTAIN-6 enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk (mean age 65, diabetes for an average of 13.9 years; 83% had established cardiovascular disease, chronic kidney disease or both). Over a median of about two years, the combination of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.6% of people on Ozempic versus 8.9% on placebo, a 26% lower relative risk (hazard ratio 0.74). This trial is the basis for Ozempic's cardiovascular indication.

In STRIDE, a 2025 trial of 792 adults with type 2 diabetes and peripheral artery disease causing leg pain when walking, Ozempic 1 mg increased maximum walking distance on a treadmill by 13% more than placebo at 52 weeks. Novo Nordisk has sought to add these data to the label; the U.S. label we reviewed (revised October 2025) does not yet include a peripheral artery disease use. See new uses for Ozempic.

Kidney protection: FLOW and the 2025 indication

FLOW enrolled 3,533 adults with type 2 diabetes and chronic kidney disease (mean eGFR 47, with significant protein in the urine) who were already on standard kidney treatment, including ACE inhibitors or ARBs in 95%. Participants received Ozempic 1 mg weekly or placebo and were followed for a median of 41 months; the trial was stopped early for efficacy.

• The main composite outcome, a 50% or greater sustained drop in eGFR, kidney failure, or death from kidney or cardiovascular causes, occurred in 18.7% on Ozempic versus 23.2% on placebo, a 24% lower risk (hazard ratio 0.76).
• Major cardiovascular events were 18% lower (12.0% vs 14.4%) and death from any cause 20% lower (12.8% vs 15.8%).
• Kidney function declined more slowly year over year.

Based on FLOW, the FDA approved Ozempic in January 2025 to reduce the risk of kidney disease worsening, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This is not a treatment for kidney disease in people without diabetes.

Ozempic with other diabetes medicines

Combined with	What to know
Metformin	The most common pairing. Semaglutide did not change metformin levels to a clinically relevant degree. Both can cause stomach upset at first.
SGLT2 inhibitors (empagliflozin, dapagliflozin and others)	No dose change needed. In SUSTAIN 9, adding Ozempic 1 mg to an SGLT2 inhibitor lowered A1C by 1.42 points more than placebo and weight by 3.81 kg more; stomach side effects affected 37.3% vs 13.2%.
Pioglitazone (a TZD)	No dose change needed.
Sulfonylureas (glipizide, glimepiride, glyburide)	Higher risk of low blood sugar. In trials, severe hypoglycemia occurred in 0.8% (0.5 mg) and 1.2% (1 mg) of people on Ozempic plus a sulfonylurea. The sulfonylurea dose may need to be lowered.
Insulin	Higher risk of low blood sugar; severe episodes occurred in 1.5% of people on Ozempic 1 mg plus basal insulin. Insulin is often reduced when Ozempic starts. Never mix the two in one syringe; separate injections may go in the same body area but not right next to each other.
DPP-4 inhibitors (sitagliptin and others)	Work through the same GLP-1 pathway; prescribers usually stop them when a GLP-1 drug starts.
Other GLP-1 drugs or tirzepatide	Not used together.

Because Ozempic slows the stomach, it could affect how other pills are absorbed. Studies found no clinically relevant change for the drugs tested, including warfarin, digoxin, atorvastatin and oral contraceptives, but the label still advises caution, so tell your clinician and pharmacist everything you take.

Signs of low blood sugar include shakiness, sweating, a racing heart, strong hunger, irritability and confusion. Treat with fast-acting sugar (glucose tablets, juice or regular soda) and tell your prescriber. People on insulin or a sulfonylurea should check their glucose more often in the first weeks on Ozempic.

Is Ozempic insulin?

No. Both come in pens and are injected under the skin, but insulin lowers blood sugar directly, while Ozempic helps your own pancreas release insulin when glucose is high. That only works if the pancreas still makes insulin. Ozempic is frequently combined with insulin: in the label's basal-insulin trial, adding Ozempic lowered A1C by 1.3 to 1.7 points (placebo 0.2) and weight by 3.5 to 6 kg. People already on insulin must not stop or slash their insulin on their own when starting Ozempic; dose changes should be gradual and directed by the prescriber.

Ozempic and type 1 diabetes

Ozempic is approved only for type 2 diabetes. In type 1 diabetes the pancreas makes little or no insulin, so insulin is essential and semaglutide cannot replace it. Researchers have studied GLP-1 drugs as add-ons in people with type 1 diabetes and obesity, but that is not an approved use, and it should be considered only with an endocrinologist. Ozempic is not a treatment for diabetic ketoacidosis.

Eyes, pancreas and other cautions

In SUSTAIN-6, complications of diabetic retinopathy occurred in 3.0% of people on Ozempic versus 1.8% on placebo, mostly in those who already had retinopathy (8.2% vs 5.2%). Rapid improvement in blood sugar can temporarily worsen the eyes, so people with retinopathy need regular eye exams. Other cautions from the label: past pancreatitis, gallbladder disease, kidney injury from dehydration, severe gastroparesis (not recommended), and a personal or family history of medullary thyroid carcinoma or MEN 2 (contraindicated). The label also advises stopping at least two months before a planned pregnancy. The full list is in Ozempic side effects.

Monitoring: A1C every three months

A1C reflects average blood sugar over roughly three months, so the effect of a dose can only be judged after a few months at that dose. Many clinicians check A1C about every three months until you reach your goal, then less often. Your personal target depends on age, how long you have had diabetes, complications and your risk of low blood sugar; for many adults it is under 7%. Expect blood pressure, cholesterol, kidney function and urine albumin to be checked as well, along with an annual eye exam.

What to do if Ozempic is not working

1. Check the dose. 0.25 mg is only a starter dose. If 0.5 mg is not enough after at least four weeks, the dose can go to 1 mg and then 2 mg.
2. Check the injections. Missed doses, skipping the flow check on a new pen, pulling the needle out too soon, or a pen that froze or overheated can all mean less drug. A missed dose can be taken within five days; after that, skip it.
3. Look at other causes. Steroids and some other drugs, infections, stress and changes in eating can push sugar up.
4. Add or switch. Basal insulin is the usual next step if A1C stays above goal; some people are moved to tirzepatide (see Ozempic vs Mounjaro and switching from Ozempic to Mounjaro).

Do not stop Ozempic on your own. Blood sugar rises once it wears off, and diabetes is a chronic disease in which effective treatment usually continues long term.

Cost and coverage for people with diabetes

Commercial plans and Medicare Part D generally cover Ozempic for type 2 diabetes, usually with prior authorization; with commercial coverage, Novo Nordisk's savings offer can lower the copay to as little as $25 a month (savings capped at $100 a month). Medicaid programs generally cover it too. Without coverage, NovoCare Pharmacy prices as of October 14, 2026 are $199 a month for the first two 0.25 or 0.5 mg fills for new patients (through December 31, 2026), $349 for 0.25 to 1 mg and $499 for 2 mg; Ozempic tablets were launched at $149 to $299. A Medicare-negotiated price for semaglutide, reported at $274 for a 30-day supply, takes effect January 1, 2027. Novo Nordisk's Patient Assistance Program provides pens at no cost to people who qualify by income and insurance status. More: Ozempic cost.

Shortages and supply

From 2022, surging demand, much of it for off-label weight loss, left Ozempic and Wegovy in shortage in the United States, and many people with diabetes struggled to fill prescriptions, especially the lower starter strengths. The FDA declared the semaglutide shortage resolved on February 21, 2025. If your pharmacy is out of stock, ask your prescriber about a short-term alternative or a different pharmacy rather than buying from an unverified seller; counterfeit Ozempic 1 mg pens have been seized in the U.S. supply chain several times since 2023. For everything else, start at our Ozempic guide. This article is general information, not medical advice.